Humacyte Announces Publication of New Data Comparing Symvess(TM) to Autologous Vein in Extremity Arterial Trauma GlobeNewswire October 30, 2025 – Results published in AAST's Trauma Surgery & Acute Care Open Journal – – Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein – – In a […]

Solesence To Report Third Quarter 2025 Financial Results and Host a Conference Call GlobeNewswire October 30, 2025 ROMEOVILLE, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) — Solesence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third quarter of

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights Akebia to Host Conference Call on November 10, 2025, at 8:00 a.m. EST GlobeNewswire October 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third

23andMe Research Institute Appoints Privacy Advisory Board GlobeNewswire October 30, 2025 PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — 23andMe Research Institute, a nonprofit medical research organization, today announced the formation of its Privacy Advisory Board. Composed of leading experts in health data privacy, data ethics, and consumer advocacy, the Board will provide strategic

Barry Hytinen Appointed to ABM's Board of Directors GlobeNewswire October 30, 2025 NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, today announced the appointment of Barry Hytinen to its Board of Directors. Mr. Hytinen currently serves as Executive Vice President and Chief Financial

Edible Garden Receives Preliminary Approval to Sell Up to $3.35 Million in Tax Credits Through NJEDA Program Authorization Positions Company to Generate Non-Dilutive, Tax-Free Capital to Support Growth, Innovation, and Sustainable Expansion GlobeNewswire October 30, 2025 BELVIDERE, NJ, Oct. 30, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL,

ORYZON to Participate in Upcoming Events in November GlobeNewswire October 30, 2025 MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena

First Mid Bancshares, Inc. Announces Third Quarter 2025 Results GlobeNewswire October 30, 2025 MATTOON, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) — First Mid Bancshares, Inc. (NASDAQ: FMBH) (the “Company”) today announced its financial results for the quarter ended September 30, 2025. Highlights Quarterly net income of $22.5 million, or $0.94 diluted EPS Adjusted quarterly net

Operative Announces New CEO to Drive Next Phase of Growth Michael Napodano Appointed CEO Of Operative Media GlobeNewswire October 30, 2025 NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — Operative today announced the appointment of Mike Napodano as Chief Executive Officer, marking the next step in the company's evolution as it accelerates platform innovation, deepens

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting GlobeNewswire October 30, 2025 SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today